Eli Lilly's stock jumped on strong financial results and advancement of its oral weight-loss drug candidate, underscoring demand for next-generation diabetes an

Medicare began covering weight-loss drugs for eligible seniors, expanding the addressable market for Novo Nordisk, Eli Lilly, and others while potentially savin

GRAIL's early cancer detection blood test could unlock significant market value if FDA grants approval, positioning the Illumina subsidiary as a leader in non-i

Vertex's CASGEVY gene-editing therapy gained expanded FDA clearance for pediatric cystic fibrosis, broadening its commercial footprint in rare genetic diseases.

Viking Therapeutics, an emerging player in the weight-loss drug space, is attracting bullish sentiment from analysts and retail investors ahead of further clini

AtaiBeckley's progression of its psilocybin-based therapy into late-stage testing and FTSE Russell index addition signal growing institutional recognition of th

Sarepta's filing acceptance for expanded indications of AMONDYS 45 and VYONDYS 53 suggests continued regulatory momentum in rare genetic disease treatment.

A presidential directive to accelerate psychedelic drug approvals boosted sentiment for companies developing psilocybin and other psychedelic treatments.

Novo's oral GLP-1 therapy is rapidly expanding its addressable market by converting patients who have never tried weight-loss drugs.

Roche's non-small-cell lung cancer drug demonstrated superiority in direct comparison, supporting competitive positioning in a major oncology segment.

Selecta Therapeutics stock surged ahead of a pivotal acute myeloid leukemia trial conclusion, with Street analysts projecting further gains on potential approva

Potential reduction of the 340B drug discount obligation would benefit manufacturers by eliminating low-margin sales to certain healthcare providers.

Ascendis's new trial results for growth hormone therapy support analyst valuations and could attract growth-focused investors to the rare endocrine disease spac

Moderna received positive FDA panel endorsement for a new indication, supporting growth prospects beyond its core mRNA vaccine platform.

Wave Life Sciences progressed its obesity-focused RNA therapeutic, entering early-stage human testing as interest in alternative obesity treatment mechanisms gr

ImmunityBio's revised filing for its bladder cancer immunotherapy, bolstered by Saudi regulatory nod, positions the asset for potential US approval.

Travere's recent approval for a rare kidney disease treatment expands its specialty pharma portfolio and provides a new revenue driver.

Psilocybin and other psychedelic compounds are gaining clinical validation as breakthrough treatments for psychiatric conditions resistant to conventional thera